HANGZHOU TIGERMED CO. H 1 Total Liabilities

Latest as of March 2026: €4.24 Billion EUR ≈ $4.95 Billion USD

HANGZHOU TIGERMED CO. H 1 total liabilities. Based on the latest financial reports, HANGZHOU TIGERMED CO. H 1 (5HZ1) has total liabilities worth €4.24 Billion EUR (≈ $4.95 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of HANGZHOU TIGERMED CO. H 1 to evaluate the company's liquid asset resilience ratio.

Total Liabilities of HANGZHOU TIGERMED CO. H 1 (2021–2025)

Total liabilities of HANGZHOU TIGERMED CO. H 1 from 2021 to 2025. This chart illustrates how HANGZHOU TIGERMED CO. H 1's total liabilities have evolved over time, based on quarterly financial data.

HANGZHOU TIGERMED CO. H 1 Competitors by Total Liabilities

The table below lists competitors of HANGZHOU TIGERMED CO. H 1 ranked by their total liabilities.

Company Country Total Liabilities
Fedbank Financial Services Limited
NSE:FEDFINA
India Rs-29.26 Billion
Nanfang Black Sesame Group Co Ltd
SHE:000716
China CN¥1.87 Billion
Aba Chemicals Corp
SHE:300261
China CN¥2.09 Billion
Zhejiang Sunflower Light Energy
SHE:300111
China CN¥153.24 Million
Far East Holdings Bhd
KLSE:5029
Malaysia RM340.51 Million
Longyan Zhuoyue New Energy Co Ltd
SHG:688196
China CN¥982.88 Million
Shenzhen Shengxunda Technology Co Ltd Class A
SHE:300518
China CN¥116.97 Million
Wecome Pharmaceutical Co Ltd
SHE:300878
China CN¥458.37 Million

Liability Composition Analysis (2021–2025)

This chart breaks down HANGZHOU TIGERMED CO. H 1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 5HZ1 current and non-current assets.

Liquidity & Leverage Metrics

HANGZHOU TIGERMED CO. H 1 Total Liabilities Ratios Explained

HANGZHOU TIGERMED CO. H 1 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 2.30 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.20 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.15 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how HANGZHOU TIGERMED CO. H 1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for HANGZHOU TIGERMED CO. H 1 (2021–2025)

The table below shows the annual total liabilities of HANGZHOU TIGERMED CO. H 1 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €4.10 Billion
≈ $4.80 Billion
-10.94%
2024-12-31 €4.61 Billion
≈ $5.39 Billion
-11.87%
2023-12-31 €5.23 Billion
≈ $6.11 Billion
+9.69%
2022-12-31 €4.77 Billion
≈ $5.57 Billion
+51.96%
2021-12-31 €3.14 Billion
≈ $3.67 Billion
--

About HANGZHOU TIGERMED CO. H 1

F:5HZ1 Germany Diagnostics & Research
Market Cap
$604.57 Million
€517.12 Million EUR
Market Cap Rank
#10957 Global
#1279 in Germany
Share Price
€4.20
Change (1 day)
-0.94%
52-Week Range
€3.22 - €5.85
All Time High
€11.40
About

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing … Read more